Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A process for separating a VWF having a high activity from a VWF having a low activity, comprising the step of performing a chromatography ~~with~~ using hydroxylapatite as a chromatography matrix.

2. (Currently Amended) A process for the production of a composition having a high specific VWF activity~~, characterized in that~~ comprising the step of purifying a VWF containing composition ~~is purified~~ by means of hydroxylapatite chromatography.

3. (Currently Amended) A process for raising the specific VWF activity of a VWF containing composition~~, characterized in that~~ comprising the step of subjecting the VWF containing composition ~~is subjected~~ to a hydroxylapatite chromatography.

4. (Currently Amended) The process according to ~~any of claims 1 to 3~~claim 1, characterized in that VWF is bound to the hydroxylapatite column matrix, VWF having a low specific activity is washed out and then VWF having a high specific activity is eluted at a relatively high salt concentration.

5. (Currently Amended) The process according to ~~any of claims 1 to 4~~claim 1, characterized in that the chromatography is carried out at a pH between 5 and 7~~, preferably between 5.5 and 6.8~~.

6. (Currently Amended) The process according to ~~any of claims 1 to 5~~claim 1, characterized in that a sodium or potassium phosphate containing solution is used as a running buffer.

7. (Currently Amended) The process according to ~~any of claims 1 to 6~~claim 1, ~~characterized in that the~~ further comprising the use of a wash buffer ~~contains~~ containing 100 – 300 mM~~, preferably 200 – 300 mM~~ sodium or potassium phosphate, and ~~the~~ an elution buffer ~~contains~~ containing 200 – 500 mM~~, preferably 300 – 400 mM,~~ sodium or potassium phosphate.

8. (Currently Amended) The process according to ~~any of claims 1 to 7~~claim 1, ~~characterized by~~further comprising the steps of initially carrying out flow chromatography with hydroxylapatite, rechromatographing the flow fraction under binding conditions and eluting ~~the target protein as~~ a highly pure VWF fraction.

9. (Currently Amended) The process according to ~~any of claims 1 to 8~~claim 1, characterized in that the hydroxylapatite is a ceramic hydroxylapatite ~~is used~~.

10. (Original) The process according to claim 9, characterized in that the ceramic hydroxylapatite is type I or type II.

11. (Currently Amended) The process according to ~~any of claims 1 to 10~~claim 1, characterized in that a previously purified plasma fraction is used as ~~the~~ a starting material.

12. (Currently Amended) The process according to ~~any of claims 1 to 11~~claim 1, characterized in that a further purified cryoprecipitate solution is used as ~~the~~ a starting material.

13. (Currently Amended) The process according to ~~any of claims 1 to 12~~claim 1, characterized in that a cryoprecipitate solution precipitated with aluminum hydroxide is used as ~~the~~ a starting material.

14. (Currently Amended) The process according to ~~any of claims 1 to 13~~claim 1, characterized in that a chromatographically pre-purified cryoprecipitate solution precipitated with aluminum hydroxide is used as ~~the~~ a starting material.

15. (Currently Amended) The process according to ~~any of claims 1 to 14~~claim 1, ~~characterized in that~~ further comprising the step of carrying out a pH precipitation ~~is carried out~~ prior to the hydroxylapatite chromatography to separate fibronectin.

16. (Currently Amended) The process according to ~~any of claims 1 to 10~~claim 1, characterized in that a protein solution with recombinantly produced VWF is used as ~~the~~ a starting material.

17. (Currently Amended) The process according to ~~any of claims 1 to 16~~claim 1, characterized in that the hydroxylapatite used contains fluoride ions.

18. (Canceled) ~~Use of hydroxylapatite for separating VWF molecules having high activity from VWF molecules having low activity.~~

19. (Canceled) ~~Use of hydroxylapatite for the production of a VWF preparation having a high specific VWF activity.~~

20. (Canceled) ~~Use of hydroxylapatite for raising the specific VWF activity of a VWF containing composition.~~

21. (Currently Amended) A VWF containing composition ~~obtainable~~ obtained by ~~a~~ the process according to ~~any of claims 1 to 16~~claim 1.

22. (Currently Amended) A VWF containing composition~~, characterized in that it has~~ having a specific activity of at least 120 U/mg protein.

23. (Currently Amended) A composition according to claim 21 ~~or 22~~, ~~characterized in that it~~ further wherein the composition has a specific VWF activity of at least 120 U/mg VWF antigen.

24. (Currently Amended) A method of treating von Willebrand syndrome comprising the step of administering ~~Use of~~ a composition according to ~~any of claims 21 to 23 for treating the von Willebrand syndrome~~claim 21 to a subject in need thereof.